Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 337-346

  Lee, Intae ^a   Shogen, Kuslima ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Alfacell Corporation   (United States)

Author keywords

Cytotoxic RNase; Lung cancer; Onconase ; Ranpirnase

Indexed keywords

EOSIN; GADODIAMIDE; HEMATOXYLIN; RANPIRNASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD FLOW; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; MULTIPLE DRUG DOSE; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STAINING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR FLUID; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PRESSURE; RIBONUCLEASES;

EID: 43749095238     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0637-y     Document Type: Article

References (26)

1. Ardelt W, Mikulski SM, Shogen K (1991) Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos: homology to pancreatic ribonucleases. J Biol Chem 266:245-251
2. Beani CP (2000) Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations. Chest 117:127s-132s
3. Costanzi J, Sidransky D, Navon A, Goldsweig H (2005) Ribonucleases as a novel pro-apoptonic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 3:643-650
4. Grabarek J, Ardelt B, Du L, Darzynkiewicz Z (2002) Activation of caspases and serine proteases during apoptosis induced by onconase (ranpirnase). Exp Cell 278:61-71
5. Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, Magun BE (2000) Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60:1983-1994
6. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
7. Kim DH, Kim EJ, Kalota A, Gewirtz AM, Glickson J, Shogen K, Lee I (2007) Possible mechanisms of improved radiation response by cytotoxic RNase, ONCONASE®, on A549 human lung cancer xenografts of nude mice. Adv Exp Med Biol 599:53-59
8. Kong FM, Zhao L, Hayman JA (2006) The role of radiation therapy in thoracic tumors. Hematol Oncol Clin North Am 20:363-400
9. Leach MO, Brindle KM, Evelhoch JL, Griffths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Proce P, Rathbone R, Rutin GJ, Tofts PS, Tozer GM, Vennart W, Waterson JC, Williams SR, Workman P (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599-1610
10. Ledoux L (1955) Action of ribonuclease on certain ascites tumours. Nature 175:258-259
11. Ledoux L (1955) Action of ribonuclease on two solid tumours in vivo. Nature 176:35-37
12. Lee I, Boucher Y, Jain RK (1992) Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 52:3237-3240
13. Lee I, Lee YH, Mikulski SM, Lee J, Covone K, Shogen K (2000) Tumoricidal effects of onconase on various tumors. J Sur Oncol 73:164-171
14. Lee I, Lee YH, Mikulski SM, Lee J, Shogen K (2000) Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by onconase. Anticancer Res 20:1037-1040
15. Lee I, Kalota A, Gerwirtz AM, Shogen K (2007) Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res 27:299-308
16. Lee I, Kim DH, Sunar U, Magnitsky S, Yodh AG, Shogen K (2006) The physiological mechanisms of ranpirnase-induced enhancement in radiation response on A549 human lung carcinoma xenografts in nude mice. Int J Radiat Oncol Biol Phys 66:s580-s581
17. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K (2001) Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20:274-281
18. Penketh PG, Shyam K, Sartorelli AC (1996) Mechanisms of resistance to alkylating agents in drug resistance. In: Hait WN (ed) Drug resistance, Kluwer, Boston, pp 65-81
19. Rutkoski TJ, Kurten EL, Mitchell JC, Raines RT (2005) Disruption of shape-complementary markers to create cytotoxic variants of ribonuclease A. J Mol Biol 354:41-54
20. Rybak SM, Newton DL (1999) Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res 253:325-335
21. Saxena SK, Sirdeshmukh R, Ardelts W, Mikulski SM, Shogen K, Youle RJ (2002) Entry into cells and selective degradation of tRNA by a cytotoxic member of the RNase A family. J Biol Chem 277:15142-15146
22. Sordella R, Bell DW, Harber DA, Settleman J (2004) Gefitinib-sensitizing EFGR mutations in lung cancer activate anti-apoptotic pathway. Science 305:1163-1167
23. L858R non-small-cell lung cancer line H3255. Cancer Res 64:7241-7244
24. Tofsts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357-367
25. Tofsts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee T, Mayr NA, Parker GJM, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetics parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
26. Vasandani VM, Burris JA, Sung C (1999) Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake. Cancer Chemother Pharmacol 44:164-169